The role of iNOS in cholesterol-induced liver fibrosis

Laboratory Investigation

Volumn 95, Issue 8, 2015, Pages 914-924

  Anavi, Sarit ^a   Eisenberg Bord, Michal ^a   Hahn Obercyger, Michal ^a   Genin, Olga ^b   Pines, Mark ^b   Tirosh, Oren ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b VOLCANI CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; HIF1A PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DNA DAMAGE; FATTY LIVER; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; LIVER INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RAT; STELLATE CELL; ANIMAL; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIPID DIET; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

ANIMALS; CELL LINE; CHOLESTEROL; DIET, HIGH-FAT; DNA DAMAGE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; RATS;

EID: 84938081206     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.67     Document Type: Article

References (66)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
2. Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol 2009;15:72-79.
3. Charlton M. Fatty liver disease; NASH and related disorders. Gastroenterology 2005;129:1801-1802.
4. Kamari Y, Shaish A, Vax E et al. Lack of interleukin-1alpha or inter-leukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol 2011;55: 1086-1094.
5. Wang W, Zhao C, Zhou J et al. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohe-patitis-related liver fibrosis. PLoS One 2013;8:e76538.
6. Farrell GC, van Rooyen D. Liver cholesterol: is it playing possum in NASH? Am J Physiol Gastrointest Liver Physiol 2012;303:G9-G11.
7. Farrell GC, van Rooyen D, Gan L et al. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012;6:149-171.
8. Teratani T, Tomita K, Suzuki T et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 2012;142:152-164 e110.
9. Tomita K, Teratani T, Suzuki T et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014;59:154-169.
10. Ioannou GN, Morrow OB, Connole ML et al. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 2009;50:175-184.
11. Van Rooyen DM, Gan LT, Yeh MM et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 2013;59:144-152.
12. Diesen DL, Kuo PC. Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention. J Surg Res 2011;167:96-112.
13. Ergun Y, Kurutas EB, Ozdil B et al. Evaluation of nitrite/nitrate levels in relation to oxidative stress parameters in liver cirrhosis. Clin Res Hepatol Gastroenterol 2011;35:303-308.
14. Mayoral P, Criado M, Hidalgo F et al. Effects of chronic nitric oxide activation or inhibition on early hepatic fibrosis in rats with bile duct ligation. Clin Sci (Lond) 1999;96:297-305.
15. Wei CL, Hon WM, Lee KH et al. Chronic administration of amino-guanidine reduces vascular nitric oxide production and attenuates liver damage in bile duct-ligated rats. Liver Int 2005;25:647-656.
16. Criado M, Flores O, Vazquez MJ et al. Role of prostanoids and nitric oxide inhibition in rats with experimental hepatic fibrosis. J Physiol Biochem 2000;56:181-188.
17. Moal F, Veal N, Vuillemin E et al. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats. World J Gastroenterol 2006;12:6639-6645.
18. Lukivskaya O, Patsenker E, Lis R et al. Inhibition of inducible nitric oxide synthase activity prevents liver recovery in rat thioacetamide-induced fibrosis reversal. Eur J Clin Invest 2008;38:317-325.
19. Patel RP, Levonen A, Crawford JH et al. Mechanisms of the pro-and anti-oxidant actions of nitric oxide in atherosclerosis. Cardiovasc Res 2000;47:465-474.
20. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497-509.
21. Anavi S, Harmelin NB, Madar Z et al. Oxidative stress impairs HIF1alpha activation: a novel mechanism for increased vulnerability of steatotic hepatocytes to hypoxic stress. Free Radic Biol Med 2012;52: 1531-1542.
22. Kupai K, Szucs G, Cseh S et al. Matrix metalloproteinase activity assays: Importance of zymography. J Pharmacol Toxicol Methods 2010;61: 205-209.
23. Anavi S, Hahn-Obercyger M, Madar Z et al. Mechanism for HIF-1 activation by cholesterol under normoxia: a redox signaling pathway for liver damage. Free Radic Biol Med 2014;71:61-69.
24. Anavi S, Hahn-Obercyger M, Margalit R et al. A novel antihypoglycemic role of inducible nitric oxide synthase in liver inflammatory response induced by dietary cholesterol and endotoxemia. Antioxid Redox Signal 2013;19:1889-1901.
25. Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech 2014;7:193-203.
26. Han YP. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J Gastroenterol Hepatol 2006;21():S88-S91.
27. Garvey EP, Oplinger JA, Tanoury GJ et al. Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. J Biol Chem 1994;269:26669-26676.
28. Han YP, Yan C, Zhou L et al. A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J Biol Chem 2007;282:12928-12939.
29. Tanaka H, Fujita N, Sugimoto R et al. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer 2008;98:580-586.
30. Farina AR, Mackay ARGelatinase B/MMP-9 in Tumour Pathogenesis and ProgressionCancers (Basel) 2014;6:240-296.
31. Prakobwong S, Yongvanit P, Hiraku Y et al. Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. Int J Cancer 2010;127:2576-2587.
32. Hill JW, Poddar R, Thompson JF et al. Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscience 2012;220: 277-290.
33. Murata M, Thanan R, Ma N et al. Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J Biomed Biotechnol 2012;2012:623019.
34. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 2007;595:105-125.
35. Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol 2012;920:613-626.
36. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-172.
37. Feldstein AE, Papouchado BG, Angulo P et al. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2005;3:384-389.
38. Cortez-Pinto H, Baptista A, Camilo ME et al. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepatogastroenter-ology 2001;48:87-90.
39. Washington K, Wright K, Shyr Y et al. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol 2000;31: 822-828.
40. Reeves HL, Burt AD, Wood S et al. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996;25:677-683.
41. Magness ST, Bataller R, Yang L et al. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004;40:1151-1159.
42. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
43. Haase VH. Hypoxia-inducible factor signaling in the development of kidney fibrosis. Fibrogenesis Tissue Repair 2012;5:S16.
44. Higgins DF, Kimura K, Bernhardt WM et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007;117:3810-3820.
45. Lokmic Z, Musyoka J, Hewitson TD et al. Hypoxia and hypoxia signaling in tissue repair and fibrosis. Int Rev Cell Mol Biol 2012;296: 139-185.
46. Moon JO, Welch TP, Gonzalez FJ et al. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol 2009;296:G582-G592.
47. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 2012;55:622-633.
48. Paternostro C, David E, Novo E et al. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol 2010;16:281-288.
49. Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010;30:258-270.
50. Li H, Mittal A, Makonchuk DY et al. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet 2009;18: 2584-2598.
51. Van den Steen PE, Dubois B, Nelissen I et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002;37:375-536.
52. Loiselle AE, Frisch BJ, Wolenski M et al. Bone marrow-derived matrix metalloproteinase-9 is associated with fibrous adhesion formation after murine flexor tendon injury. PLoS One 2012;7:e40602.
53. Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009;296:G1324-G1331.
54. Gadd VL, Melino M, Roy S et al. Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C. Liver Int 2013;33:569-579.
55. Chen Y, Hozawa S, Sawamura S et al. Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem Biophys Res Commun 2005;326:45-51.
56. Heilpern AJ, Wertheim W, He J et al. Matrix metalloproteinase 9 plays a key role in lyme arthritis but not in dissemination of Borrelia burgdorferi. Infect Immun 2009;77:2643-2649.
57. Birrell MA, Wong S, Dekkak A et al. Role of matrix metalloproteinases in the inflammatory response in human airway cell-based assays and in rodent models of airway disease. J Pharmacol Exp Ther 2006;318:741-750.
58. Jeong S, Ledee DR, Gordon GM et al. Interaction of clusterin and matrix metalloproteinase-9 and its implication for epithelial homeostasis and inflammation. Am J Pathol 2012;180:2028-2039.
59. O'Sullivan S, Medina C, Ledwidge M et al. Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance-NO and MMP-9 interactions. Biochim Biophys Acta 2014; 1843:603-617.
60. Shimizu I, Shimamoto N, Saiki K et al. Lipid Peroxidation in Hepatic Fibrosis 2012.
61. Ichiba M, Maeta Y, Mukoyama T et al. Expression of 8-hydroxy-2'-deoxyguanosine in chronic liver disease and hepatocellular carcinoma. Liver Int 2003;23:338-345.
62. Daugherity EK, Balmus G, Al Saei A et al. The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle 2012;11: 1918-1928.
63. Bopp A, Wartlick F, Henninger C et al. Rac1 modulates acute and subacute genotoxin-induced hepatic stress responses, fibrosis and liver aging. Cell Death Dis 2013;4:e558.
64. Yue HY, Yin C, Hou JL et al. Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut 2010;59:236-246.
65. Kim MR, Kim HS, Lee MS et al. Cell cycle protein profile of the hepatic stellate cells(HSCs)in dimethylnitrosamine-induced rat hepatic fibrosis. Exp Mol Med 2005;37:335-342.
66. Hughes KJ, Meares GP, Chambers KT et al. Repair of nitric oxide-damaged DNA in beta-cells requires JNK-dependent GADD45alpha expression. J Biol Chem 2009;284:27402-27408.